Carboplatin derivatives with superior antitumor activity compared to the parent compound

Inorganica Chimica Acta

Volumn 357, Issue 15, 2004, Pages 4452-4466

  Bernhardt, Günther ^a   Brunner, Henri ^a   Gruber, Nick ^a   Lottner, Christian ^a   Pushpan, Simi K ^a   Tsuno, Takashi ^b   Zabel, Manfred ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CARBOXYLIC ACIDS; CELLS; DISEASES; LIGANDS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ACTIVE COMPOUNDS; ANTI-PROLIFERATIVE ACTIVITIES; ANTI-TUMOR ACTIVITIES; BLADDER CANCER CELLS; CARBOXYLIC ACID GROUPS; CYTOSTATIC ACTIVITIES; OVARIAN CANCER CELLS; PARENT COMPOUNDS;

PLATINUM COMPOUNDS;

1,2 DIAMINOCYCLOHEXANE; AMMONIA; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOXYLIC ACID DERIVATIVE; CISPLATIN; CYCLOBUTANE; LIGAND; PLATINUM DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CONTROLLED STUDY; CYTOSTASIS; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY CARCINOMA;

EID: 9244244737     PISSN: 00201693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ica.2004.03.060     Document Type: Article

References (28)

1. B. Rosenberg, L. Van Camp, and T. Krigas Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698
2. R.B. Weiss, and M.C. Christian New cisplatin analogues in development. A review Drugs 46 1993 360
3. E. Wong, and C.M. Giandomenico Current status of platinum-based antitumor drugs Chem. Rev. 99 1999 2415
4. T.W. Hambley Platinum binding to DNA: structural controls and consequences J. Chem. Soc. Dalton Trans. 120 2001 2711
5. D. Lebwohl, and R. Canetta Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Eur. J. Cancer 34 1998 1522
6. N. Gruber, Ph.D. Thesis, Universität Regensburg, 2002
7. W.A. Nevill, D.S. Frank, and R.D. Trepka Free radical chlorination of cyclobutanecarboxylic acids J. Org. Chem. 27 1962 422
8. M. Avram, C.D. Nenitzescu, and M. Maxim Cyclobutane series. I. 1,3-disubstituted cyclobutane derivatives Chem. Ber. 90 1957 1424
9. C. Beard, and A. Burger cis- and trans-3-Dimethylamino-1-cyclobutanol Chem. Ber. 95 1962 2535
10. W.R. Dolbier Jr., T.A. Gray, J.J. Keaffaber, L. Celewiz, and H. Koroniak Kinetic and thermodynamic effects in the thermal electrocyclic ring-openings of 3fluorocyclobutene, 3,3-difluorocyclobutene, and 3-(trifluoromethyl)cyclobutene J. Am. Chem. Soc. 112 1990 363
11. G.S. Lal, G.P. Pez, R.J. Pesaresi, and F.M. Prozonic Bis(2-methoxyethyl) aminosulfur trifluoride: a new broad-spectrum deoxofluorinating agent with enhanced thermal stability Chem. Commun. 1999 215
12. G.S. Lal, G.P. Pez, R.J. Pesaresi, F.M. Prozonic, and H. Cheng Bis(2-methoxyethyl)aminosulfur trifluoride: a new broad-spectrum deoxofluorinating agent with enhanced thermal stability J. Org. Chem. 64 1999 7048
13. G.G. Furin L. German S. Zemskov New Fluorinating Agents in Organic Synthesis 1989 Springer-Verlag Berlin 35
14. R.D. Allan, J.R. Hanrahan, T.W. Hambley, G.A.R. Johnston, K.N. Mewett, and A.D. Mitrovic Synthesis and activity of a potent N-methyl-d-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids J. Med. Chem. 33 1990 2905
15. L.D. Jennings, R.D. Rayner, D.B. Jordan, J.F. Okonya, G.S. Basarab, D.K. Amorose, B.M. Anaclerio, J.K. Lee, R.D. Schwartz, and K.A. Whitmore Cyclobutane carboxamide inhibitors of fungal melanin: biosynthesis and their evaluation as fungicides Bioorg. Med. Chem. 8 2000 897
16. H. Brunner, F. Maiterth, and B. Treittinger Synthese und Antitumoraktivität neuer Porphyrin-Platin(II)-Komplexe mit an den Porphyrin-Seitenketten gebundenem cytostatischen Platin-Rest Chem. Ber. 127 1994 2141
17. Y. Kidani, K. Inagaki, M. Iigo, A. Hoshi, and K. Kuretani Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form J. Med. Chem. 21 1978 1315
18. C. Lottner, K.-C. Bart, G. Bernhardt, and H. Brunner Hematoporphyrin- derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity J. Med. Chem. 45 2001 2064
19. C.M. O'Toole M.M. Webber In Vitro Models for Cancer Research vol. IV 1986 CRC Press Boca Raton, FL 103
20. B.T. Hill, D.H. Whelan, E.M. Gibby, D. Sheer, L.K. Hesking, S.A. Shellard, and H.T. Rupniak Establishment and characterization of three new human ovarian cancer cell lines and initial evaluation of their potential in experimental chemotherapy studies Int. J. Cancer 39 1987 219
21. G. Bernhardt, R. Müller, R. Gust, H. Reile, C. Keller, T. Spruß, and H. Schönenberger Dichloro [1-hydroxyphenyl)-2- phenylethylenediamine]platinum(II) complexes. Testing on the human ovarian cancer cell lines NIH:OVCAR-3 and SK-OV-3 Arch. Pharm. Pharm. Med. Chem. 325 1992 93
22. H. Reile, H. Birnböck, G. Bernhardt, T. Spruß, and H. Schönenberger Computerized determination of growth kinetic curves and doubling times from cells in microculture Anal. Biochem. 187 1990 262
23. G. Bernhardt, H. Reile, H. Birnböck, T. Spruß, and H. Schönenberger Standardized kinetic microassay to quantitate differential chemosensitivity based on proliferative activity J. Cancer Res. Clin. Oncol. 118 1992 35
24. A.R. Khokhar, G. Lumetta, and L. Sheryl A convenient method for the preparation of antitumor carboxylato(1,2-diaminocyclohexane)platinum(II) complexes Inorg. Chim. Acta 151 1988 87
25. R.J. Hay The seed stock concept and quality control for cell lines Anal. Biochem. 171 1988 225
26. T.C. Hamilton, R.C. Young, W.M. McKoy, K.R. Grotzinger, J.A. Green, E.W. Chu, J. Whang-Peng, A.M. Rogan, W.R. Green, and R.F. Ozols Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with andogen and estrogen receptors Cancer Res. 43 1983 5379
27. G. Bernhardt, R. Gust, H. Reile, H.-D. vom Orde, R. Müller, C. Keller, T. Spruß, H. Schönenberger, T. Burgemeister, A. Mannschreck, K.-J. Range, and U. Klement [1,2-Bis(2-hydroxyphenyl)ethylenediamine] dichloroplatinum(II), a new compound for the therapy of ovarian cancer. Part II: Synthesis preliminary testing of the enantiomeric complexes J. Cancer Res. Clin. Oncol. 118 1992 201
28. T. Spruß, G. Bernhardt, E. Schickaneder, and H. Schönenberger Different response of murine and human mammary tumor models to a series of diastereoisomeric [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum(II) complexes J. Cancer Res. Clin. Oncol. 117 1991 435